- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06060990
Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers
September 27, 2023 updated by: Institute of Oncology Ljubljana
The aim of the study is to determine the total concentration of selected trace elements (Cu, Zn, Fe), the proportion of free Cu and Cu bound to ceruloplasmin and the isotopic ratio of Cu65/Cu63 in blood serum samples from healthy volunteers and cancer patients using inductively coupled plasma mass spectrometry-based methods.
The results will be statistically evaluated and the potential applications of the analytical methods used in cancer diagnosis and therapy will be assessed.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Copper, zinc and iron (Cu, Zn and Fe) are among the trace metals that are essential for the normal functioning of the human body.
They are involved in many biochemical reactions, are cofactors of enzymes, regulate important biological processes by binding to specific receptors and transcription factors.
Their concentration in the organism is influenced by many factors such as gender, age, food, environmental pollution, etc. Deregulation of trace metal homeostasis, both at the cellular and tissue level, is part of the pathology of many cancers.
It accelerates the transformation of normal cells into cancerous ones, and alters the inflammatory and anti-tumour response of immune cells such as macrophages).
Knowledge of the role of essential trace metals in cancer is important for the development of modern pharmaceutical and nutritional approaches aimed at restoring the balance of trace elements in the body and enhancing the beneficial effects of systemic oncological therapy.
At the same time, the results of modern research on the imbalance of essential trace metals point to their usefulness in cancer diagnosis and therapy.
Biliary tract cancers (BTCs) are a heterogeneous group of uncommon and rare epithelial tumours.
Surgery is the only potential curative treatment for BTCs, but approximately 70% of patients are diagnosed at advanced stages due to absence of specific symptoms in early stage.
Tumour markers can be diagnostic, for tumour screening and early detection, prognostic or predictive for response to systemic oncological therapy.
However, widely accepted biomarkers for diagnosing and dynamically monitoring the BTCs are still lacking.
Currently applied tumour markers CA 19-9 and CEA, have limited diagnostic value for BTCs because they don't have high sensitivity and specificity for BTCs.
Trace elements as biomarkers in oncology are new research field for detecting, diagnosing and prediction of response to treatment.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Martina Reberšek, MD,PhD
- Phone Number: 00386 15879975
- Email: mrebersek@onko-i.si
Study Locations
-
-
-
Ljubljana, Slovenia
- Recruiting
- Institute of Oncology Ljubljana
-
Contact:
- Martina Reberšek, MD, PhD
- Phone Number: 00386 15879975
- Email: mrebersek@onko-i.si
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- aged ≥18 years
- cytologically or histologically verified biliary tract cancer
- no prior systemic therapy and no radiation therapy for advanced, inoperable or metastatic disease
- WHO performance status 0 - 2 (ECOG criteria)
- imaging diagnosis (CT of thoracic and abdominal organs) performed within 4 weeks prior to the first administration of systemic therapy
- disease measurable by RECIST or ECOG criteria
- signed Consent to Participate in Clinical Research form
Exclusion Criteria:
- prior systemic treatment and radiation therapy for inoperable, metastatic disease
- WHO performance status > 2 (ECOG criteria)
- contraindications to immunotherapy (known immunodeficiency or active immunosuppressive therapy or active autoimmune disease requiring treatment)
- other malignancies, except cured basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or other cured solid tumours without recurrence ≥ 3 years after treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Open-label single arm of patients with metastatic BTCs
Systemic therapy: Identification of trace elements as novel predictive and prognostic biomarkers for response to systemic therapy in metastatic BTCs |
trace elements as biomarkers for response to systemic therapy in metastatic BTCs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum copper (Cu) as a predictive biomarker of the response to systemic treatment of biliary tract cancer patients
Time Frame: 3 years
|
The concentration of copper (Cu) in blood serum samples from healthy volunteers and biliary cancer patients will be measured to identify the differences in levels and the ratio between both groups, and to identify the serum Cu levels as a predictive biomarker of response to systemic therapy biliary tract cancer patients in the correlation with radiological CT evaluation.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Martina Reberšek, MD, PhD, Institute of Oncology Ljubljana
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2023
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
September 13, 2023
First Submitted That Met QC Criteria
September 27, 2023
First Posted (Actual)
September 29, 2023
Study Record Updates
Last Update Posted (Actual)
September 29, 2023
Last Update Submitted That Met QC Criteria
September 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KME 0120-472/2022/3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trace Element Deficiency
-
Hamilton Health Sciences CorporationLondon Health Sciences CentreCompletedRenal Insufficiency, Chronic | Zinc Deficiency | Trace Element Excess | Trace Element DeficiencyCanada
-
The Hospital for Sick ChildrenRare Disease Foundation Microgrant competitionCompleted
-
Centre Hospitalier Universitaire VaudoisCompletedCritical Illness | Burn Injury | Nutritional Deficiency | Trace Element DeficiencySwitzerland
-
University Medicine GreifswaldCompletedObesity | Obesity, Morbid | Vitamin Deficiency | Protein Malnutrition | Trace Element Deficiency | Mineral DeficiencyGermany
-
Chang Gung Memorial HospitalCompletedSepsis | Critical Illness | Acute Abdomen | Selenium Deficiency | Trace Element DeficiencyTaiwan
-
Rabin Medical CenterRecruiting
-
ElsanEuropean Clinical Trial Experts NetworkCompletedMetallic Trace Elements | Metal-type Environmental PollutantsFrance
-
Cairo UniversityRecruitingTrace Elements Levels After Breast Cancer RadiotherapyEgypt
-
Louqiang ZhangApproved for marketingMandible Fracture | Rigid Internal Fixation | Three-dimensional Finite ElementChina
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
Clinical Trials on trace elements
-
Centre Hospitalier Universitaire VaudoisCompletedCritical Illness | Burn Injury | Nutritional Deficiency | Trace Element DeficiencySwitzerland
-
Cengiz Gokcek Women's and Children's HospitalCompleted
-
Hospices Civils de LyonCompletedChronic HemolysisFrance
-
University of California, San FranciscoCompleted
-
Kasr El Aini HospitalCompleted
-
St. John's Research InstituteUnilever R&DCompleted
-
Fundació Institut Germans Trias i PujolGermans Trias i Pujol HospitalCompleted
-
University of British ColumbiaMinistry of Health, Zambia; UNICEF; Tropical Disease Research CentreCompleted
-
University of California, DavisUnited States Agency for International Development (USAID); Nestlé FoundationCompleted
-
Francesca De FilippisCompletedEnvironmental-Pollution-Related Condition